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Purpose: Alterations of the plasmin system have been suggested to participate in the multifactorial pathogenesis of primary
open-angle  glaucoma  (POAG).  The  main  physiological  inhibitor  of  the  plasmin  system  is  plasminogen  activator
inhibitor-1 (PAI-1), which leads to decreased degradation of extracellular material. Interestingly, elevated PAI-1 levels
in the aqueous humor of patients with POAG have been reported. A common polymorphism within the promoter region
(PAI-1 4G/5G) has previously been shown to reduce the gene transcription rate of PAI-1. The purpose of the present study
was to investigate a hypothesized association between PAI-1 4G/5G and the presence of POAG in a Caucasian population.
Methods: The present case-control study comprised 212 unrelated patients with POAG and 212 healthy control subjects,
matched for age and sex. Genotyping of PAI-1 4G/5G polymorphisms was done using polymerase chain reaction.
Results: Allelic frequencies and genotype distributions of PAI-1 4G/5G did not significantly differ between patients with
POAG and control subjects (PAI-1 4G/5G: 29.7% versus 29.7%). Presence of the PAI-1 4G-allele was associated with a
nonsignificant odds ratio of 0.98 (95% confidence interval: 0.74–1.30) for POAG.
Conclusions: Our data suggest that PAI-1 4G/5G itself is unlikely to be a major risk factor among Caucasian patients
with POAG.
Primary open-angle glaucoma (POAG; OMIM 137760)
is one of the major causes of blindness throughout the world
[1]. Elevated intraocular pressure (IOP) is the most important
and so far the only therapeutically modifiable risk factor [2].
Accumulation  of  extracellular  material  (ECM)  in  the
trabecular  meshwork,  which  may  be  due  to  enhanced
production  or  reduced  degradation  of  ECM,  has  been
suggested to lead to elevated IOP [3,4].
The serine protease plasmin has a central position in the
fibrinolytic  pathway,  thereby  restoring  blood  flow  after
thrombotic events. In addition, it also has a key role in the
degradation and proteolysis of ECM via modulation of growth
factors, cytokines, and metalloproteinases [5]. Plasminogen is
converted to plasmin by the action of urokinase (u-PA) and
tissue plasminogen activator (t-PA). The main physiological
inhibitor  of  u-PA  and  t-PA  is  plasminogen  activator
inhibitor-1 (PAI-1; OMIM 173360), a glycoprotein composed
of 379 amino acids, which forms a stable complex with both
u-PA and t-PA [6]. It was shown that PAI-1 protects ECM
from t-PA and plasminogen mediated degradation [7].
There is ample evidence for a physiological role of the
plasmin system in the anterior segment of the eye and the
trabecular outflow system in particular. Activity of u-PA, t-
PA, and PAI-1 has been found in the human aqueous humor
[8-11].  In  an  in  vitro  study,  Shuman  and  coworkers  [12]
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demonstrated that in trabecular meshwork cells, t-PA activity
outweighs the inhibitor activity. Fuchshofer and coworkers
[13]  found  a  significant  increase  of  PAI-1  expression  in
cultures of human TM cells after treatment with TGF-β2,
which  leads  to  the  expression  of  active  matrix
metalloproteinase-2  (MMP-2).  Reduction  of  resistance  to
aqueous outflow was observed after perfusion of monkey eyes
with plasmin [14]. It can thus be hypothesized that increased
levels of PAI-1 may lead to decreased proteolysis of ECM in
the trabecular meshwork, subsequently leading to an increase
in IOP. Indeed, two recent studies reported elevated PAI-1
levels  in  the  aqueous  humor  of  patients  with  open-angle
glaucoma compared to cataract patients [15,16].
A common functional polymorphism within the promoter
region due to a single guanosine insertion/deletion, 4G/5G
(rs1799889), has been identified [17]. The PAI-1 5G allele
leads to binding of a repressor protein thereby decreasing gene
transcription.  Consequently,  higher  plasma  PAI-1
concentrations have been found among homozygotes for the
4G- allele compared to heterozygotes and homozygotes for
the  5G-allele  [17-19].  However,  a  recent  study  found  no
association  between  the  PAI-1  4G/5G  polymorphism  and
expression of PAI-1 in platelets [20].
Since POAG is a disease with a high heritability as shown
in  population  based  studies  [21,22],  our  study  was  set  to
investigate a hypothesized association between the PAI-1 4G/
5G polymorphism and the presence of POAG.
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The present study was comprised of 212 patients with POAG
and 212 control subjects. All participants were seen at the
Department  of  Ophthalmology,  Medical  University  Graz
(Graz, Autria) between September 2002 and November 2005.
All participants were Caucasians from the same geographical
area in the southern part of Austria. Informed consent was
obtained from all subjects before enrollment. The study was
conducted in accordance with the standards of the local ethics
committee and the National Gene Technology Act.
All patients underwent slit lamp biomicroscopy as well
as  testing  for  best  corrected  visual  acuity,  Goldmann
applanation  tonometry,  gonioscopy,  pachymetry,  and
standard  automated  perimetry  (Interzeag  Octopus  101,
program G2) or – in cases of profoundly decreased visual
acuity – Goldmann perimetry. In all patients, photographs of
the optic disc were taken. POAG was defined by an intraocular
pressure  of  at  least  21  mmHg  before  the  initiation  of  a
pressure-lowering therapy, an open anterior chamber angle,
optic  disc  changes  characteristic  for  glaucoma  (increased
vertical cup/disc ratio of more than or equal to 0.7), visual
field defects characteristic for glaucoma (inferior or superior
arcuate  scotoma,  nasal  step,  or  paracentral  scotoma),  and
absence of conditions leading to secondary glaucoma. Optic
discs were assessed by glaucoma specialists (GM and CF).
The  control  group  consisted  of  212  patients  with  no
morphological or functional damage indicative for primary or
secondary  open-angle  or  angle  closure  glaucoma.  Control
subjects were admitted to our department for cataract surgery
and were matched to cases by sex and age (±3 years). Medical
history concerning arterial hypertension and diabetes mellitus
was obtained from all participants.
Genotype determination: Genomic DNA was isolated
from venous blood by standard methods and stored at –20 °C.
PAI-1 genotypes were determined by a 5′-exonuclease assay
(TaqMan, Applied Biosystems, Vienna, Austria). Primer and
probe sets were designed and manufactured using Applied
Biosystems  ‘Assay-by-Design’  custom  service  (Applera,
Austria).  The  polymerase  chain  reaction  (PCR)  was
performed in a Primus 96 plus thermal cycler (MWG Biotech
AG,  Ebersberg,  Germany)  using  a  total  volume  of  5  μl
containing 2.5 μl Universal Genotyping MasterMix (Applied
Biosystems), 0.125 μl 40X Assay-by-Design mix (Applied
Biosystems), 0.375 μl H2O, and 2 μl DNA. Reactions were
overlaid with 15 μl of mineral oil. Cycling parameters were
as follows primary denaturation was for 10 min at 94 °C
followed by 40 cycles for 20 s at 92 °C and for 1 min at 60 °C.
Fluorescence was measured in a lambda Fluoro 320 Plus plate
reader (MWG Biotech AG) using excitation/emission filters
of 485 nm/530 nm for FAM-labeled probes (4G-allele) and
530 nm/572 nm for VIC-labeled probes (5G-allele). The data
were exported into Excel format and depicted and analyzed
as a scatter plot.
To validate the genotyping method, we also determined
PAI-1 genotypes of 24 samples, which had been analyzed
previously by a polymerase chain reaction and endonuclease
digestion  method  [23].  Results  of  both  methods  were
consistent in all samples.
Statistical analysis: Descriptive statistics were used to
calculate frequencies and percentages of discrete variables.
Continuous data are given as mean±standard deviation (SD).
Means  were  compared  using  the  Mann–Whitney  test.
Proportions of groups were compared by χ2 test. Odds ratio
(OR) and 95% confidence interval (95% CI) were calculated
by logistic regression. The criterion for statistical significance
was p≤0.05. Statistical analysis was done using the SPSS
statistical package (SPSS, version 14.0, Chicago, Illinois).
RESULTS
The present study comprised 212 patients (125 female and 87
male) with POAG and 212 controls (125 female and 87 male).
The mean age of patients was 71.5±9.8 years, and the mean
age  of  control  subjects  was  70.9±9.6  years.  Clinical
characteristics of patients and control subjects are shown in
Table 1. Patients had a mean deviation of 11.5±6.7 dB, a mean
loss  of  variance  of  38.0±27.6  square  decibel,  a  mean
intraocular pressure of 21.8±15.4 mmHg, and a mean cup disc
ratio of 0.79±0.13 in the worse eye. In 34 patients (16%), a
trabeculectomy with mitomycin C has been performed, and in
19 patients (9%), a transscleral cyclophotocoagulation has
been  performed  while  44  patients  (20.8%)  had  both
interventions. Seventy-two patients (34%) were treated with
prostaglandin analogs, 44 patients (20.8%) were treated with
β-blockers,  23  patients  (10.8%)  were  treated  with
brimonidine, and 17 patients (8%) were treated with carbonic
anhydrase inhibitors.
No significant differences in either genotype distribution
or allelic frequencies of the PAI-1 4G/5G polymorphism were
found  between  patients  with  POAG  and  control  subjects
(Table 2). Presence of the PAI-1 4G-allele was associated with
an odds ratio of 0.98 (95% CI: 0.74–1.30) for POAG. The
present study had a statistical power of 0.80 to detect an odds
ratio of 1.77 for the PAI-1 4G/5G genotype in patients with
POAG.
The observed genotype distributions did not deviate from
those predicted by the Hardy-Weinberg equilibrium, and for
control subjects, the genotype distributions were similar to
those reported for Caucasian populations [24,25].
DISCUSSION
The balance between plasmin activators and inhibitors is of
utmost importance not only for vascular homeostasis but also
for extracellular proteolysis. Alterations of the plasmin system
potentially leading to reduced degradation of ECM in the
trabecular  meshwork  have  been  implicated  in  the
pathogenesis of POAG. Interestingly, elevated levels of PAI-1
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only  recently  [15,16].  Gene  polymorphisms  leading  to
increased  synthesis  of  PAI-1  may  thus  contribute  to  the
pathogenesis of POAG. To the best of our knowledge, the
present  study  is  the  first  to  investigate  a  hypothesized
association between PAI-1 4G/5G and the presence of POAG.
Genotypes  of  PAI-1  4G/5G  were  determined  in  212
patients  with  POAG  and  212  control  subjects  that  were
matched  for  age  and  sex.  Allelic  frequencies  as  well  as
genotype distributions did not significantly differ between
both groups. As the study has a statistical power of 0.80 to
detect an odds ratio of 1.77 for the PAI-1 4G/5G genotype in
patients with POAG, our data suggest that the investigated
polymorphism  is  unlikely  a  major  genetic  risk  factor  for
POAG in Caucasian patients.
Potentially, elevation of the PAI-1 level in the aqueous
humor may result from reduced aqueous humor turnover in
patients  with  POAG.  Furthermore,  synthesis  of  PAI-1  is
regulated by various factors. Hyperglycemia as well as insulin
and insulin precursor molecules stimulate the transcription of
PAI-1 [26-28]. Angiotensin II, very low density lipoproteins,
and unsaturated fatty acids induce the expression of PAI-1
whereas  estrogen  suppresses  synthesis  of  PAI-1  [29-32].
Moreover, cytokines like TGF-β2 and tumor necrosis factor-α
increase  PAI-1  expression  [33-35].  In  an  in  vitro  study,
Fleenor and coworkers provided evidence that treatment of
trabecular  meshwork  with  TGF-β2  increased  secretion  of
PAI-1, which led to elevated IOP [33]. Thus, our finding that
the PAI-1 4G/5G polymorphism is not associated with an
increased risk for POAG does not exclude a substantial role
of PAI-1 in the pathogenesis of POAG.
In conclusion, no statistically significant difference in the
genotype distribution of the PAI-1 4G/5G polymorphism was
found  between  patients  with  POAG  and  control  subjects,
which  strongly  suggests  that  this  polymorphism  itself  is
unlikely a major risk-factor for POAG.
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